SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000882104-19-000099
Filing Date
2019-09-13
Accepted
2019-09-12 21:49:03
Documents
4
Period of Report
2019-09-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pdli-201909138xkdoc.htm 8-K 47432
2 CONVERTIBLE NOTES EXCHANGE AGREEMENT pdli-201909138xkex101.htm EX-10.1 127324
3 PRESS RELEASE pdli-201909138xkex991.htm EX-99.1 17473
4 pdllogoa26.jpg GRAPHIC 123123
  Complete submission text file 0000882104-19-000099.txt   363109
Mailing Address 932 SOUTHWOOD BLVD INCLINE VILLAGE NV 89451
Business Address 932 SOUTHWOOD BLVD INCLINE VILLAGE NV 89451 775-832-8500
PDL BIOPHARMA, INC. (Filer) CIK: 0000882104 (see all company filings)

IRS No.: 943023969 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-19756 | Film No.: 191091458
SIC: 2836 Biological Products, (No Diagnostic Substances)